Tg Therapeutics (TGTX) Research & Development (2011 - 2026)

Tg Therapeutics' Research & Development history runs 16 years deep, the most recent figure standing at $43.5 million for Q1 2026.

• In Q1 2026, Research & Development fell 6.13% year-over-year to $43.5 million; the TTM figure through Mar 2026 stood at $152.0 million (up 45.12% YoY), while the FY2025 annual figure was $160.2 million, up 92.73% from the prior year.
• Research & Development for Q1 2026 stood at $43.5 million, up from $41.2 million in the prior quarter.
• The five-year high for Research & Development was $48.0 million in Q1 2022, with the low at $11.8 million in Q3 2023.
• The 5-year median for Research & Development is $26.9 million (2022), against an average of $27.9 million.
• The sharpest annual moves came in 2022 and 2024: Research & Development plunged 71.54% in 2022, then surged 106.19% in 2024.
• Tg Therapeutics' Research & Development stood at $16.4 million in 2022, then gained by 6.33% to $17.4 million in 2023, then grew by 18.71% to $20.7 million in 2024, then surged by 98.87% to $41.2 million in 2025, then climbed by 5.65% to $43.5 million in 2026.
• Business Quant data shows TGTX's Research & Development at $43.5 million in Q1 2026, $41.2 million in Q4 2025, and $35.5 million in Q3 2025.